View in EDS

Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers.

Saved in:
Bibliographic Details
Title: Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers.
Authors: Tyc KM; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA., Kazi A; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA., Ranjan A; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA., Wang R; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA., Sebti SM; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
Source: IScience [iScience] 2023 Jan 31; Vol. 26 (3), pp. 106082. Date of Electronic Publication: 2023 Jan 31 (Print Publication: 2023).
Publication Type: Journal Article
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36852277
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Tyc+KM%22">Tyc KM</searchLink>; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.<br /><searchLink fieldCode="AU" term="%22Kazi+A%22">Kazi A</searchLink>; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.<br /><searchLink fieldCode="AU" term="%22Ranjan+A%22">Ranjan A</searchLink>; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.<br /><searchLink fieldCode="AU" term="%22Wang+R%22">Wang R</searchLink>; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.<br /><searchLink fieldCode="AU" term="%22Sebti+SM%22">Sebti SM</searchLink>; Department of Pharmacology and Toxicology, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101724038%22">IScience</searchLink> [iScience] 2023 Jan 31; Vol. 26 (3), pp. 106082. <i>Date of Electronic Publication: </i>2023 Jan 31 (<i>Print Publication: </i>2023).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Cell+Press%22">Cell Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101724038 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2589-0042 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225890042%22">25890042 </searchLink><i>NLM ISO Abbreviation: </i>iScience <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36852277
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.isci.2023.106082
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 106082
    Titles:
      – TitleFull: Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Tyc KM
      – PersonEntity:
          Name:
            NameFull: Kazi A
      – PersonEntity:
          Name:
            NameFull: Ranjan A
      – PersonEntity:
          Name:
            NameFull: Wang R
      – PersonEntity:
          Name:
            NameFull: Sebti SM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 31
              M: 01
              Text: 2023 Jan 31
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 2589-0042
          Numbering:
            – Type: volume
              Value: 26
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: IScience
              Type: main
ResultId 1